Vaccines and the Infectious Diseases They Prevent

Image representing the teeth of a bat with IMOVAX RABIES and IMOGRAM RABIES-HT writen below

Characteristics of IMOGAM Rabies–HT Immune Globulin

IMOGAM Rabies–HT Immune Globulin contains human antibodies that are extracted from the blood of people who have already been vaccinated with IMOVAX Rabies vaccine and developed antibodies to the rabies virus^1,2

An added heat-treatment (HT) process (58°C to 60°C, for 10 hours) to inactivate viruses is used to further reduce any risk of blood-borne viral transmission¹

IMOGAM Rabies–HT Immune Globulin contains no preservatives; unused portions should be discarded immediately¹

IMOGAM Rabies–HT Immune Globulin is standardized against the United States (US) Standard Rabies Immune Globulin; the US unit of potency
is equivalent to the International Unit (IU) for rabies antibody. The minimal potency is 150 IU/mL^1,2

View full Prescribing Information for IMOGAM Rabies–HT Immune Globulin.

References: 1. IMOGAM Rabies–HT Prescribing Information, December 2005. 2. Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-21.

IMOVAX® Rabies

Indication

IMOVAX Rabies vaccine is indicated for active, pre- and post-exposure immunization against rabies.

Safety Information
The most common local and systemic adverse reactions to IMOVAX Rabies vaccine may include injection site pain, erythema, and swelling; headache, nausea, and muscle aches. Other adverse reactions may occur. Once initiated for post-exposure treatment rabies vaccination should not be interrupted or discontinued because of mild local or systemic adverse reactions. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents. Vaccination with IMOVAX Rabies vaccine may not protect all individuals.

Before administering IMOVAX Rabies vaccine, please see accompanying full Prescribing Information.

IMOGAM® Rabies–HT

Indication
IMOGAM Rabies-HT immune globulin is given for passive immunization of individuals suspected of exposure to rabies.

Safety Information
Side effects to the IMOGAM Rabies-HT immune globulin include injection site tenderness, pain, and muscle soreness or stiffness. Other side effects may occur. IMOGAM Rabies-HT immune globulin should not be given in repeated doses once vaccine treatment has begun. IMOGAM Rabies-HT immune globulin is made from components of human blood and, therefore, this vaccine may carry a risk of transmitting infectious material, although careful selection of donors and extensive testing are intended to minimize this risk. Treatment with a rabies immune globulin may not protect all individuals.

For more information about IMOGAM Rabies-HT immune globulin, talk to your health-care professional.

Last modified: 5/2/08